https://scholars.lib.ntu.edu.tw/handle/123456789/496072
標題: | Metformin may reduce oral cancer risk in patients with type 2 diabetes | 作者: | CHIN-HSIAO TSENG | 關鍵字: | Diabetes mellitus; Metformin; Oral cancer; Taiwan | 公開日期: | 2016 | 出版社: | Impact Journals LLC | 卷: | 7 | 期: | 2 | 起(迄)頁: | 2000-2008 | 來源出版物: | Oncotarget | 摘要: | Background: Whether metformin use may affect the risk of oral cancer required further investigation. Methods: The reimbursement database of the National Health Insurance in Taiwan was used. Patients with type 2 diabetes mellitus at an onset age of 25-74 years during 1999-2005 and newly treated with either metformin (n = 288198, "ever users of metformin") or other antidiabetic drugs (n = 16263, "never users of metformin") were followed for at least 6 months for oral cancer until December 31, 2011. The treatment effect of metformin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression adjusted for propensity score (PS) or incorporated with the inverse probability of treatment weighting (IPTW) using PS. Results: The respective numbers of incident oral cancer in ever users and never users were 1273 (0.44%) and 119 (0.73%), with respective incidences of 92.7 and 163.6 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) suggested a significantly lower risk [0.584 (0.483-0.707) for PS-adjusted model, and 0.562 (0.465-0.678) for IPTW model]. In tertile analyses, the PS-adjusted hazard ratios (95% confidence intervals) for the first (< 21.5 months), second (21.5-45.9 months) and third (> 45.9 months) tertile of cumulative duration were 1.403 (1.152-1.708), 0.557 (0.453-0.684) and 0.152 (0.119-0.194), respectively; and were 1.244 (1.024-1.511), 0.526 (0.429-0.645) and 0.138 (0.108-0.176), respectively, for IPTW. Conclusions: Metformin may significantly reduce the risk of oral cancer, especially when the cumulative duration is more than 21.5 months. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957665963&doi=10.18632%2foncotarget.6626&partnerID=40&md5=d5b3c151f875620cee11d58bad51b52b https://scholars.lib.ntu.edu.tw/handle/123456789/496072 |
ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.6626 | SDG/關鍵字: | antidiabetic agent; insulin; metformin; antidiabetic agent; metformin; add on therapy; adult; aged; Article; cancer incidence; cancer prevention; cancer risk; controlled study; drug effect; drug exposure; drug use; female; hazard ratio; human; major clinical study; male; mouth cancer; non insulin dependent diabetes mellitus; observational study; risk reduction; Taiwan; treatment duration; case control study; comparative study; complication; Diabetes Mellitus, Type 2; follow up; middle aged; Mouth Neoplasms; prognosis; risk factor; Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mouth Neoplasms; Prognosis; Risk Factors |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。